Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

Proper management of COVID-19 mandates better understanding of disease pathogenesis.
The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe …

BCG vaccination in children protects against heterologous infections and improves survival
independently of tuberculosis prevention. The phase III ACTIVATE trial assessed whether …

Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

Background A subanalysis of a randomized clinical trial indicated sepsis survival benefit
from interleukin (IL)-1 blockade in patients with features of the macrophage activation-like …

Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has
shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in …

Itaconate is an immunomodulatory metabolite produced by immune cells under microbial
stimulation and certain pro-inflammatory conditions and triggers antioxidant and anti-…

Background: The validation of new biomarkers for the diagnosis and risk stratification of
patients with sepsis at an early point is essential for successful treatment. Recent publications …

Acute respiratory distress syndrome (ARDS) in COVID-19 has been associated with
catastrophic inflammation. We present measurements in humans and a new animal model …

The trajectory from moderate and severe COVID-19 into acute respiratory distress syndrome
(ARDS) necessitating mechanical ventilation (MV) is a field of active research. We …